Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,University Of Pennsylvania ,Stuart Henderson ,Mike Beyer ,Healthcare Communications ,Sam Brown Inc ,University Of Pennsylvania Gene Therapy Program ,Nasdaq ,Passage Bio Inc ,Nasdaq Listing Rule ,Passage Bio ,Inducement Options ,Gene Therapy Program ,Bio Investors ,Bio Media ,Markets ,